NasdaqGS:HALOBiotechs
Halozyme Therapeutics (HALO) Q4 Loss On US$451.8m Revenue Tests ENHANZE Profit Narrative
Halozyme Therapeutics (HALO) closed out FY 2025 with fourth quarter revenue of US$451.8 million and a basic EPS loss of US$1.20, compared with Q4 2024 revenue of US$298.0 million and basic EPS of US$1.08. Over the past year, the company has seen quarterly revenue move from US$290.1 million in Q3 2024 to US$354.3 million in Q3 2025, while basic EPS shifted from US$1.08 to US$1.49 over the same quarters, creating a mixed picture for margins as investors digest the latest numbers.
See our full...